Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9 editing in human cells. Pending an appeal to the Federal Circuit, this decision ends the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and Broad.

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q4 2021 Results - Earnings Call Transcript

EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

Aerie Pharmaceuticals

Emergent BioSolutions

Moderna

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should Know

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

CRISPR Therapeutics

Intellia Therapeutics

Sangamo Therapeutics

Our theme of Gene Editing stocks continues to underperform, declining by about 16% year-to-date in 2022, compared to the S&P 500 which is down by about 6% over the same period. The theme also declined by about 11% in 2021.

The Sell Off In Gene Editing Stocks Continues. Time To Buy?

Editas Medicine Inc EDIT has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Editas Suddenly Terminates Chief Medical Officer Without An Explanation

Krystal Biotech

For these two companies, the rewards could end up outweighing the risks.

2 Biotech Stocks That Could Skyrocket This Year

The overall sell-off of biotech stocks appears to be the main culprit.

Why Editas Medicine Stock Is Tumbling This Week

Editas Medicine, Inc. (EDIT) JPMorgan 40th Annual Healthcare Conference (Transcript)

Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

Beam Therapeutics

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

The Best CRISPR Companies to Invest In

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

Editas Medicine is a gene-editing technology company. Editas Medicine has lost over 60% of its value.

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Our theme of Gene Editing stocks remains down by about 11% year-to-date, considerably underperforming the S&P 500 which is up by a solid 23% over the same period. The theme would have actually declined by about 46% year-to-date if we exclude a single stock, Intellia Therapeutics, which is up by.

Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

One would have hoped that EDIT chose a more aggressive portfolio that matches its cutting-edge tech. Instead, it decided to walk a more trodden path.

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Bristol-Myers

Check out these pharmaceutical players on the move now.

Good Stocks To Buy Right Now? 3 Pharmaceutical Stocks In Focus

After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading. The post EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today appeared first on InvestorPlace.

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today

The stock price of Editas Medicine Inc (NASDAQ: EDIT) increased by over 9% pre-market today. This is why it happened.

Editas Medicine Stock (EDIT): Why The Price Jumped Today

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Adagio Therapeutics

SPDR S&P Biotech ETF

All three of these biotech stocks lost around half their value over the past few months.

3 Beaten-Down Biotech Stocks -- Are They Bargains Now?

The heavy selling pressure might have exhausted for Editas (EDIT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News for Editas Medicine Stock (EDIT)